The Globe and Mail

New Data Presented at SABCS 2022 Reveal Expanded Predictive Value of the Breast Cancer Index™ Test for Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer

Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with ...
Fierce Healthcare

Not enough hospitals are testing their predictive AI models for accuracy, bias, study finds

Many U.S. hospitals using predictive models are not evaluating their tools internally for accuracy, and fewer still are evaluating them for potential biases, according to a study published in the most ...
Business Wire

Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced newly published study results revealing that use of the Breast Cancer Index ...
Cure Today

Tumor Test May Predict Which Patients With HR-Positive Breast Cancer Will Benefit From Ovarian Suppression

Recent research sought to determine which patients with HR-positive breast cancer can benefit by adding ovarian function suppression to their adjuvant regimens, and which patients can skip it. A tumor ...